key: cord-0693915-a5glkhby
authors: Benza, Raymond L.; Kanwar, Manreet K.; Raina, Amresh; Scott, Jacqueline V.; Zhao, Carol L.; Selej, Mona; Elliott, C. Greg; Farber, Harrison W.
title: Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in Patients with Pulmonary Arterial Hypertension
date: 2020-09-01
journal: Chest
DOI: 10.1016/j.chest.2020.08.2069
sha: 0bf9b87e52867ad37d3c6ea4528e60d19dcca550
doc_id: 693915
cord_uid: a5glkhby

Background Achievement of low-risk status is a treatment goal in pulmonary arterial hypertension (PAH). Risk assessment is often performed using multiparameter tools, such as the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) risk calculator. Risk calculators that assess fewer variables without compromising validity may expedite risk assessment in the routine clinic setting. We describe the development and validation of REVEAL Lite 2, an abridged version of REVEAL 2.0. Research Questions To develop and validate a simplified version of the REVEAL 2.0 risk assessment calculator for patients with PAH. Study Design and Methods: REVEAL Lite 2 includes six non-invasive variables: functional class (FC), vital signs (systolic blood pressure [SBP] and heart rate), six-minute walk distance (6MWD), brain natriuretic peptide (BNP)/N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and renal insufficiency (by estimated glomerular filtration rate [eGFR]) and was validated in a series of analyses (Kaplan–Meier, concordance index, Cox proportional-hazard model and multivariate analysis). Results REVEAL Lite 2 approximates REVEAL 2.0 at discriminating low, intermediate, and high risk for 1-year mortality in patients in the REVEAL registry. The model indicated that the most highly predictive REVEAL Lite 2 parameter was BNP/NT-proBNP, followed by 6MWD and FC. Even if multiple, less predictive variables (heart rate, SBP, eGFR) were missing, REVEAL Lite 2 still discriminated among risk groups. Interpretation REVEAL Lite 2, an abridged version of REVEAL 2.0, provides a simplified method of risk assessment that can be implemented routinely in daily clinical practice. REVEAL Lite 2 is a robust tool that provides discrimination between patients at low, intermediate, and high risk of 1-year mortality.

[WHO] group 1 pulmonary hypertension), there is still no cure for this progressive and ultimately fatal disease. However, with timely and effective clinical intervention, clinical status and survival are improved.

The current goal of PAH treatment is to enable patients to achieve a low mortality risk status, which has been associated with improved outcomes. [1] [2] [3] [4] [5] To enable such outcomes, assessments of mortality risk should be made at PAH diagnosis and at regular intervals during follow-up. The results of these assessments should be used to guide management, including proactive adjustment of treatment if a low mortality risk status is not achieved. 1, 5 Current best practice is for risk assessments to be made using multiparameter risk assessment tools, such as the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator, versions 1.0 or 2.0, 6, 7 the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) method, 8 the Swedish PAH Register (SPAHR) method, 9 the French Pulmonary Hypertension Registry (FPHR) method, 10 and the Bologna strategy. 11 hypertension guidelines. 8, 10, 11 Of clinical importance, REVEAL 2.0, when compared with COMPERA and FPHR showed greater risk discrimination than either of the two ESC/ERS-based risk assessment strategies. 7 The need for timely and regular risk assessment in PAH is widely acknowledged 1, 5, 10, 12, 13 ; however, realworld evidence indicates that risk assessment in the clinical setting is suboptimal. 14 Several barriers to practical implementation have been documented, including the complexity of tools, 15 the number of parameters that need to be included (with a reported 41% of patients excluded from risk calculation analysis due to insufficient measurements), and a desire to avoid potentially unnecessary invasive procedures.

To expedite risk assessment in the clinic, where comprehensive data for all patients may be lacking and time constrained, risk assessment tools using fewer variables may be preferable. 1, 7 For the REVEAL 2.0 assessment, and based on the 1-year mortality outcomes in the REVEAL derivation data (with scores ranging from 0 to 23), a score between 0 and 6 was considered low risk, a score of 7 or 8 was considered intermediate risk, and a score of 9 or higher was considered high risk. 7 For the REVEAL Lite 2 assessment (with scores ranging from 1 to 14), a score between 1 and 5 was considered low risk, a score of 6 or 7 was considered intermediate risk, and a score of 8 or higher was considered high risk. Risk was calculated for both risk calculators using data from a subpopulation of the REVEAL registry who had survived ≥1 year post-enrollment. In order to provide proper reference for REVEAL Lite 2 to REVEAL 2.0, the same data set used for REVEAL 2.0 was also used for REVEAL Lite 2. REVEAL Lite 2 scores at time of enrollment were recalculated for patients included in this analysis. 

In total, 2,529 of the 3,515 patients enrolled in REVEAL were eligible for inclusion in our analyses (e- Figure 1 ). Proportions of patients with available data for each variable and handling of missing data were previously reported. 7 Patient demographics and clinical characteristics for these patients at 1 year postenrollment are presented in Table 2 . Approximately 50% of patients had idiopathic PAH (IPAH) and 25%

had connective tissue-associated PAH (CTD-PAH). The majority of patients (approximately 87%) were classified as NYHA FC II/III. Table 3 .

These data show that REVEAL Lite 2 approximates the "parent" REVEAL 2.0 risk calculator at discriminating between patients at low, intermediate, or high risk for 1-year mortality (based on c-index).

This was the case regardless of whether the data were compared using categorical or numerical values. 

Cox proportional-hazard multivariable analysis showed that all variables and scores were independent prognosticators of survival and that higher risk score was associated with higher risk of death (e- Table 1 ). Table 2 ).

All parameters were found to be highly predictive (based on chi-squared value for individual variables), with the exceptions of heart rate and NYHA/WHO FC I. It is important to note, however, that only 203 

Agreement between REVEAL 2.0 and REVEAL Lite 2 was examined using the simple Kappa method and is presented in Table 4 . With all patients included and missing variables scored as zero (Analysis 1;

N=2,529), the agreement between the two methods using the simple Kappa method was "good," at 0.62 (good=0.61-0.80). When risk scores were calculated based on patients without missing BNP/NT-proBNP or 6MWD values (Analysis 2; n=1,505), the Kappa value improved to 0.67 (and the lower boundary of the CI increased to 0.64). With either Analysis 1 or Analysis, there were no patient assessed as low risk using REVEAL 2.0 who was found to be at high risk using REVEAL Lite 2.

J o u r n a l P r e -p r o o f

The impact of missing variables was evaluated using c-index. Scenarios of missing one, two, and three variables were used. The results are presented in Table 5 . patients (see Table 5 ). When any one of six variables were missing, the c-index was ≥ 0.70 indicating good discrimination. Missing one of the variables having higher prognostic value was associated with greater reduction in discrimination. When one to three variables from the three "least important" variables were missing (ie, eGFR, and/or SBP, and/or heart rate), REVEAL Lite 2 still provided good discrimination between risk groups. However, when two variables from the top three variables (BNP/NT-proBNP, 6MWD, and NYHA/WHO FC) were missing, the c-index would be < 0.70, which is below the threshold for good discrimination. In clinical settings, limitations in data availability, as well as time constraints, may make a risk assessment strategy that assesses fewer variables (such as REVEAL Lite 2) more practical than existing methods. In our analyses, we looked at the impact of missing data on REVEAL Lite 2, and found that even if all three of the variables classed as least valuable were missing (ie, heart rate, SBP, and eGFR), REVEAL Lite 2 still provided good discrimination between risk groups. In clinical practice, however, it would be very rare for patients to be missing many of the six variables used in REVEAL Lite 2. Furthermore, REVEAL Lite 2 achieved good discrimination when applied at enrollment demonstrating that it can be used at the appropriate time point in routine clinical practice when patients begin therapy. Another potential advantage of using REVEAL Lite 2 is that like its parent risk calculator (REVEAL 2.0), REVEAL Lite 2 uses weighting of variables. Weighting is achieved by assigning an integer score to a risk factor; this score is proportional to its contribution to the overall risk rating. The use of weighting improves the degree of agreement between predicted and observed risk. 7 Other risk assessment tools, such as the FPHR, J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f NYHA/WHO FC, n=99; heart rate, n=6; renal insufficiency, n=0; systolic blood pressure, n=8.

6MWD, 6-minute walk distance; BNP, brain natriuretic peptide; bpm, beats per minute; CI, confidence interval; FC, functional class; HR, heart rate; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; REVEAL, Registry to Evaluate Early and Long-Term PAH Disease Management; SBP, systolic blood pressure; WHO, World Health Organization.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

Assessing risk in pulmonary arterial hypertension: what we know, what we don't

Risk assessment tools in pulmonary arterial hypertension. Prognosis for prospective trials?

Time for a paradigm shift to goal-oriented clinical trial endpoints?

Risk stratification and medical therapy of pulmonary arterial hypertension

The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension

Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies

Mortality in pulmonary arterial hypertension: prediction by the

European pulmonary hypertension guidelines risk stratification model

A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

Simplified table for risk stratification in patients with different types of pulmonary arterial hypertension

Risk assessment in pulmonary arterial hypertension patients: the long and short of it

Risk assessment in pulmonary arterial hypertension

Assessment of risk of disease progression in pulmonary arterial hypertension: insights from an international survey of clinical practice

Risk assessment tools in pulmonary arterial hypertension (PAH): a survey of real-world practices and barriers to use

Retrospective validation of the REVEAL 2.0 risk score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort

Guarantor statement: RLB takes responsibility for the content of the manuscript, including the data and